Integra LifeSciences (NASDAQ:IART) Reaches New 12-Month Low After Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) reached a new 52-week low on Friday after Wells Fargo & Company lowered their price target on the stock from $13.00 to $12.00. Wells Fargo & Company currently has an equal weight rating on the stock. Integra LifeSciences traded as low as $10.60 and last traded at $11.33, with a volume of 1253512 shares changing hands. The stock had previously closed at $11.59.

Other equities research analysts have also issued reports about the company. Citigroup decreased their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research report on Friday, October 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. increased their price target on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Finally, Truist Financial reissued a “hold” rating and issued a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $14.80.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q4 results: adjusted EPS of $0.83 topped consensus ($0.79) and revenue of $434.9M beat estimates — a near-term fundamental positive that likely supported buying. Integra Surprises With Q4 Sales
• Positive Sentiment: Management highlighted operational progress and a simplified operating model expected to deliver $25–$30M of savings in 2026, underpinning margin improvement expectations. Press Release (GlobeNewswire)
• Positive Sentiment: Core Codman Specialty Surgical segment showed organic growth (neurosurgery, ENT, instruments, strong international sales), offsetting weakness elsewhere and supporting recurring revenue quality. Segment Details
• Neutral Sentiment: Analyst/editor pieces highlight momentum metrics and style scores (useful for some investors) but are not new company-specific catalysts. Zacks Momentum Article
• Neutral Sentiment: Earnings call/transcripts and slide deck are available for deeper read — useful for investors who want management color on remediation, tariffs and execution. Earnings Call Transcript
• Negative Sentiment: Guidance mixed: FY-2026 adjusted EPS of $2.30–$2.40 and revenue guidance imply modest growth, but Q1 EPS guidance ($0.37–$0.45) is below consensus — a near-term headwind for sentiment. Guidance Details
• Negative Sentiment: Legacy issues: the company recorded a $511M goodwill impairment in 2025 and reported a GAAP net loss for the year; leverage remains elevated (net debt ~ $1.6B, ~4.5x leverage), which raises capital-allocation and downside risk concerns. Quiver / Results Summary
• Negative Sentiment: Analyst action: Wells Fargo lowered its price target from $13 to $12 and set an “equal weight” rating, which can cap near-term upside. Wells Fargo PT Cut (Benzinga)

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently made changes to their positions in IART. Allianz Asset Management GmbH grew its stake in Integra LifeSciences by 88.7% in the third quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock valued at $6,215,000 after acquiring an additional 203,834 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at approximately $2,407,000. Systematic Financial Management LP increased its stake in Integra LifeSciences by 12.8% during the 2nd quarter. Systematic Financial Management LP now owns 1,056,920 shares of the life sciences company’s stock worth $12,968,000 after purchasing an additional 120,086 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Integra LifeSciences during the 2nd quarter worth approximately $632,000. Finally, Edgestream Partners L.P. bought a new position in Integra LifeSciences in the second quarter valued at approximately $739,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The company’s fifty day moving average price is $11.96 and its two-hundred day moving average price is $13.19. The company has a market cap of $886.39 million, a price-to-earnings ratio of -1.69 and a beta of 1.04.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.28%. The firm had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. During the same period in the prior year, the business earned $0.97 EPS. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.